What is Cagrilintide? A Researcher's Guide to the Long-Acting Amylin Analogue

Cagrilintide is a long-acting synthetic analogue of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. It has attracted significant research interest as a complement to GLP-1 receptor agonists, with studies investigating its effects on appetite regulation, gastric emptying, and body weight — particularly in combination with semaglutide (the CagriSema combination).

What is Cagrilintide?

Cagrilintide is an acylated amylin analogue engineered for extended half-life, enabling once-weekly dosing in research models. Native amylin has a very short half-life and is rapidly degraded, limiting its research utility. Cagrilintide’s fatty acid modification enables albumin binding, extending its duration of action to approximately one week.

Its primary receptor targets are:

  • Amylin receptors (AMY1–3) — heterodimers of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMPs); expressed in the hypothalamus, brainstem, and area postrema

Mechanism of Action

Cagrilintide acts centrally via amylin receptors in the hypothalamus and brainstem to regulate energy balance:

  • Appetite suppression — activates amylin receptors in the area postrema and nucleus tractus solitarius, reducing food intake
  • Gastric emptying — slows gastric emptying, contributing to satiety and post-meal glucose regulation
  • Glucagon suppression — reduces post-meal glucagon secretion, complementing insulin action
  • Complementary to GLP-1R agonism — amylin and GLP-1 receptors are expressed in overlapping but distinct brain regions, providing additive appetite-suppressing effects when combined

Why Cagrilintide is of Research Interest

Cagrilintide’s distinct mechanism from GLP-1 receptor agonists makes it a valuable research tool for combination studies. Key areas of ongoing research include:

  • Obesity and body weight regulation models
  • Combination amylin + GLP-1 receptor agonism (CagriSema studies)
  • Appetite regulation and central satiety signalling
  • Type 2 diabetes and glycaemic control
  • Gastric emptying and post-meal metabolism
  • Comparative amylin analogue pharmacology

Cagrilintide vs. Semaglutide vs. CagriSema

Understanding Cagrilintide’s position in the metabolic peptide landscape:

  • Semaglutide — GLP-1R agonist; well-characterised appetite and metabolic effects
  • Cagrilintide — amylin analogue; complementary central appetite suppression via distinct receptor system
  • CagriSema — fixed-ratio combination; studied for additive/synergistic effects on body weight reduction

Sourcing Cagrilintide for Research

Research-grade Cagrilintide should be sourced from suppliers providing batch-specific Certificates of Analysis (CoA) confirming purity (>98%), identity, and potency. Lyophilised formats offer optimal stability for laboratory storage.

At Aura Peptides, our Cagrilintide is supplied as a research-grade lyophilised peptide with full CoA documentation, available as single vials or in 10x bulk packs for high-volume research programmes.

For research purposes only. Not intended for human or veterinary use.

Back to blog